These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 8415211)

  • 1. [Immunogenicity of semisynthetic human insulin Novo--five year prospective studies].
    Rogala H; Czyzyk A; Lawecki J
    Pol Arch Med Wewn; 1993 Jun; 89(6):492-8. PubMed ID: 8415211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of human insulin (Novo) or pork monocomponent insulin in HLA-DR-typed insulin-dependent diabetic individuals.
    Schernthaner G; Borkenstein M; Fink M; Mayr WR; Menzel J; Schober E
    Diabetes Care; 1983; 6 Suppl 1():43-8. PubMed ID: 6343038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of monocomponent human and porcine insulin in newly diagnosed type 1 (insulin-dependent) diabetic children.
    Heding LG; Marshall MO; Persson B; Dahlquist G; Thalme B; Lindgren F; Akerblom HK; Rilva A; Knip M; Ludvigsson J
    Diabetologia; 1984 Jul; 27 Suppl():96-8. PubMed ID: 6383927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Normalization of complement activation and consumption in diabetic children and adolescents after switch-over from porcine to semisynthetic human insulin.
    Dorchy H; Duchateau J; D'Hooge D
    Diabete Metab; 1988; 14(4):415-21. PubMed ID: 3066649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transfer from purified porcine insulins to semisynthetic human insulins decreases insulin antibodies and circulating immune complexes in diabetic children and adolescents. A two-year follow-up.
    Dorchy H; Duchateau J; Bosson D; D'Hooge D
    Diabete Metab; 1989; 15(3):107-10. PubMed ID: 2668052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A twelve month double-blind randomized study of the efficacy and immunogenicity of human and porcine insulins in non-insulin-dependent diabetics.
    HO LT; Lam HC; Wu MS; Kwok CF; Jap TS; Tang KT; Wang LM; Liu YF
    Zhonghua Yi Xue Za Zhi (Taipei); 1991 May; 47(5):313-9. PubMed ID: 1649672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of efficacy and safety of human insulin (Novo) in the treatment of insulin-dependent diabetes mellitus: a double-blind, multicenter clinical trial.
    Karam J; Brink S; Clements R; Miller L; Raskin P
    Diabetes Care; 1983; 6 Suppl 1():56-60. PubMed ID: 6343041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circadian profiles of blood glucose and plasma free insulin during treatment with semisynthetic and biosynthetic human insulin, and comparison with conventional monocomponent preparations.
    Castillo M; Nemery A; Verdin E; Lefebvre PJ; Luyckx AS
    Eur J Clin Pharmacol; 1983; 25(6):767-71. PubMed ID: 6363099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The antigenicity of various new chromatographically purified depot insulin preparations].
    Graber D; Fankhauser S
    Schweiz Med Wochenschr; 1978 Nov; 108(46):1807-9. PubMed ID: 715418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction in insulin antibodies 42 months after transfer from porcine to human monocomponent insulins.
    Virgili F; Frigato F; Magnanini PG; Coronel GA; Iavicoli M
    Diabetes Res; 1988 Sep; 9(1):19-20. PubMed ID: 3071441
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical experiences with monocomponent insulins].
    Bruni Bocher K; Giolitti A; Turco GL; Benedetto P; Bruni B
    Minerva Med; 1975 Mar; 66(19):909-30. PubMed ID: 1124144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigenicity of "monocomponent" pork insulin in diabetic subjects.
    Yue DK; Turtle JR
    Diabetes; 1975 Jul; 24(7):625-32. PubMed ID: 1171804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunogenicity of MC Lente Novo insulin].
    Rogala H; Lawecki J; Czyzyk A
    Pol Arch Med Wewn; 1986 Sep; 76(3):172-6. PubMed ID: 3554163
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunogenicity of recombinant DNA human insulin.
    Fineberg SE; Galloway JA; Fineberg NS; Rathbun MJ; Hufferd S
    Diabetologia; 1983 Dec; 25(6):465-9. PubMed ID: 6198228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The use of human insulin in cases of insulin allergy].
    Gerö L; Kerényi Z; Bányai Z; Tamás G
    Orv Hetil; 1989 May; 130(22):1159-62. PubMed ID: 2668841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled study comparing treatment with monocomponent insulin and conventional insulin in patients with lipoatrophy.
    Czyzyk A; Rogala H; Lawecki J
    Acta Diabetol Lat; 1989; 26(1):17-26. PubMed ID: 2665407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of the antibody anti-insulin titer using Christiansen's radioimmunoelectrophoresis in clinical diabetology].
    Bruni Bocher K; Castellazzi R; D'Adda A; Gamba S; Giolitti A; Rittatore R; Turco GL; Bruni B
    Ann Osp Maria Vittoria Torino; 1975; 18(1-6):26-52. PubMed ID: 1242089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative double-blind trial of the effectiveness and antigenicity of semisynthetic human insulin and purified porcine insulin in newly treated diabetic subjects.
    Larkins RG; Zajac J; Saunders R; Read A; Hopper JL
    Aust N Z J Med; 1986 Apr; 16(2):206-10. PubMed ID: 3530226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human (semisynthetic) insulin and porcine insulin in the treatment of non-insulin-dependent diabetes. A double-blind, comparative clinical trial.
    Moffitt PS; Colagiuri S; Miller JJ; Hall CA
    Med J Aust; 1984 Feb; 140(4):200-2. PubMed ID: 6363896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody formation and insulin requirements in diabetic children during treatment with purified commercial pork insulins.
    Weber B; Tech J; Schmidt H; Oberdisse U
    Eur J Pediatr; 1978 Jun; 128(2):89-102. PubMed ID: 566669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.